Abstract
Sickle cell disease, though monogenic, exhibits complex clinical variability driven by genetic, epigenetic, and environmental factors. This commentary highlights advances in precision therapies and underscores the urgent need for equitable access, global collaboration, and personalized approaches to address the significant health disparities impacting individuals with sickle cell disease worldwide.